Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

ammatory disease collaboration with GSK.

Conference Call

At 08:30 a.m. Eastern Time today, August 6, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may listen to the call by dialing 866-788-0538 and refer to passcode "isis2009," or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as Regulus, its majority-owned subsidiary, and the therapeutic and commercial potential of the Company's technologies and products
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip ... to 2019" report to their offering. ... knee replacement was valued at $4,470.9 million ...
(Date:5/21/2015)... , May 21, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... quarterly cash dividend for the second quarter 2015 of ... cash dividend of $0.03 per share will be paid ... record as of June 12, 2015.  The ex-dividend date ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... AMSTERDAM, December 2 Amsterdam Molecular,Therapeutics ... gene therapy,announced today a number of management changes. Piers ... December 1, 2009. Hans,Preusting, PhD (age 47), Director Process ... and Project Management, also,effective December 1. These changes reflect ...
... BEACH, Calif., Dec. 1 Reproductive Partners Medical Group, ... Program to provide a financial incentive for patients with ... to consider reducing the chance of twins by transferring ... reproductive technology today is reducing the number of multiple ...
Cached Medicine Technology:AMT Announces Management Changes in Light of Refocused Strategy 2AMT Announces Management Changes in Light of Refocused Strategy 3Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2
(Date:5/25/2015)... 2015 Tunstall Americas announces major investment ... level of service to its Medical Answering Service customers. ... restructuring of resources, Tunstall now provides a seamless transition ... Answering Service to ensure superior patient satisfaction. ... invested over $10 million in expanded facilities and the ...
(Date:5/24/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... many patients for concerns about hair loss. Although it ... is clear that there are environmental factors such as ... that can contribute. Since they offer a comprehensive approach ... the peri and post-menopausal woman, they can help patients ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
(Date:5/24/2015)... May 24, 2015 A report ... that the single best option for avoiding cardiovascular disease ... fitness level was the single most powerful predictor of ... such as diabetes and family history of premature death ... lifelong heart and lung fitness. , The Importance of ...
(Date:5/23/2015)... 23, 2015 On Wednesday, May 20, ... company has been the target of a sophisticated cyberattack,” ... the company’s ongoing Information Technology (IT) security efforts in ... , The most notable attack on health insurers was ... the nation’s second largest health insurer, revealed that they ...
Breaking Medicine News(10 mins):Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... It,s known that people who live or work in rural ... injuries compared to those in more urban environments. But while ... rates, new research suggests that limited access to early, high-quality ... factor. Researchers from St. Michael,s in Toronto looked at ...
... study by doctors at Mount Sinai Hospital in New ... an offshoot of medical tourism, which focuses solely on ... the practice of transplant tourism where patients travel to ... their transplantation. These transplant tourists may be subject ...
... ... ... National Heart Month, and Oldways and the Mediterranean Foods Alliance offer ... the Mediterranean region. Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean ...
... chance of pregnancy by up to 50%, researchers say, , ... to a common chemical that,s used as a flame retardant ... , The chemicals, called PBDEs (polybrominated diphenyl ethers), are found ... carpets, plastics and other common household items and have been ...
... chemo-surgery regimen, researchers say , TUESDAY, Jan. 26 ... promise against locally advanced rectal cancer. , The ... rectal cancer, meaning they have a high likelihood ... receiving standard chemotherapy and optimum surgery. , For ...
... ... Interaction Associates details three essential actions for leaders to move an organization from conflict ... when not handled successfully. To download the white paper, go here: http://bit.ly/8ZcCNt ... Cambridge, ...
Cached Medicine News:Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Transplant tourism poses ethical dilemma for US doctors 2Health News:Transplant tourism poses ethical dilemma for US doctors 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3Health News:Flame-Retardant Chemical Linked to Conception Problems 2Health News:Flame-Retardant Chemical Linked to Conception Problems 3Health News:Intensive Rectal Cancer Treatment Shows Promise 2Health News:From Conflict to Consensus: Interaction Associates Outlines How Leaders Can Achieve Successful Alignment and Implementation 2Health News:From Conflict to Consensus: Interaction Associates Outlines How Leaders Can Achieve Successful Alignment and Implementation 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: